CompletedNot Applicable

Homocysteine in Critically Ill Preeclampsia

Egypt70 participantsStarted 2024-01-19

Plain-language summary

Preeclampsia is a disorder characterized by the new onset of hypertension and proteinuria typically presenting after 20 weeks of gestation. Elevated circulating homocysteine is a risk factor for endothelial dysfunction and vascular diseases such as atherosclerosis and occlusive disorders. Our study is to investigate the association between elevated blood homocysteine levels and complications in pregnant women in order to conclude the clinical utility of homocysteine as a marker of severity in the cases of pre-eclampsia.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients diagnosed by preeclampsia will be included in light of the following diagnostic criteria (blood pressure more than 140\\90 mm\\Hg on 2 occasions at least 4 hours apart after 20 weeks' gestation in a previously normotensive patient accompanied by Protein/creatinine ratio ≥0.3 . Exclusion Criteria: * Essential hypertension suggested by history or documentation of hypertension in pre pregnant state or hypertension before 20 weeks of gestation. * Cardiovascular or renal failure * Liver failure * Diabetes mellitus * Inflammatory or infective disorders * History or documentation of epilepsy in prepregnant state * Space occupying lesion in brain like tuberculoma or brain tumor * Trauma to brain * Hyperpyrexia * On treatment with antifolate drugs such as methotrexate

What they're measuring

homocysteine level

Timeframe: within 24 hours postoperative(post delivery)

Trial details

NCT IDNCT06413576

SponsorAin Shams University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-04-10

View on ClinicalTrials.gov More Pre-Eclampsia trials